215 related articles for article (PubMed ID: 17003222)
1. Increased renal phosphodiesterase-5 activity mediates the blunted natriuretic response to ANP in the pregnant rat.
Knight S; Snellen H; Humphreys M; Baylis C
Am J Physiol Renal Physiol; 2007 Feb; 292(2):F655-9. PubMed ID: 17003222
[TBL] [Abstract][Full Text] [Related]
2. Increased cGMP phosphodiesterase activity mediates renal resistance to ANP in rats with bile duct ligation.
Ni XP; Safai M; Gardner DG; Humphreys MH
Kidney Int; 2001 Apr; 59(4):1264-73. PubMed ID: 11260387
[TBL] [Abstract][Full Text] [Related]
3. Phosphodiesterase inhibitors correct resistance to natriuretic peptides in rats with Heymann Nephritis.
Valentin JP; Ying WZ; Sechi LA; Ling KT; Qiu C; Couser WG; Humphreys MH
J Am Soc Nephrol; 1996 Apr; 7(4):582-93. PubMed ID: 8724892
[TBL] [Abstract][Full Text] [Related]
4. Increased renal phosphodiesterase-5 activity mediates the blunted natriuretic response to a nitric oxide donor in the pregnant rat.
Sasser JM; Ni XP; Humphreys MH; Baylis C
Am J Physiol Renal Physiol; 2010 Oct; 299(4):F810-4. PubMed ID: 20668100
[TBL] [Abstract][Full Text] [Related]
5. Increased activity of cGMP-specific phosphodiesterase (PDE5) contributes to resistance to atrial natriuretic peptide natriuresis in the pregnant rat.
Ni XP; Safai M; Rishi R; Baylis C; Humphreys MH
J Am Soc Nephrol; 2004 May; 15(5):1254-60. PubMed ID: 15100365
[TBL] [Abstract][Full Text] [Related]
6. Cellular basis for blunted volume expansion natriuresis in experimental nephrotic syndrome.
Valentin JP; Qiu C; Muldowney WP; Ying WZ; Gardner DG; Humphreys MH
J Clin Invest; 1992 Oct; 90(4):1302-12. PubMed ID: 1328296
[TBL] [Abstract][Full Text] [Related]
7. Compartmentalization of cardiac beta-adrenergic inotropy modulation by phosphodiesterase type 5.
Takimoto E; Belardi D; Tocchetti CG; Vahebi S; Cormaci G; Ketner EA; Moens AL; Champion HC; Kass DA
Circulation; 2007 Apr; 115(16):2159-67. PubMed ID: 17420342
[TBL] [Abstract][Full Text] [Related]
8. Maximizing the renal cyclic 3'-5'-guanosine monophosphate system with type V phosphodiesterase inhibition and exogenous natriuretic peptide: a novel strategy to improve renal function in experimental overt heart failure.
Chen HH; Huntley BK; Schirger JA; Cataliotti A; Burnett JC
J Am Soc Nephrol; 2006 Oct; 17(10):2742-7. PubMed ID: 16928803
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of cGMP-specific phosphodiesterase type 5 reduces sodium excretion and arterial blood pressure in patients with NaCl retention and ascites.
Thiesson HC; Jensen BL; Jespersen B; Schaffalitzky de Muckadell OB; Bistrup C; Walter S; Ottosen PD; Veje A; Skøtt O
Am J Physiol Renal Physiol; 2005 May; 288(5):F1044-52. PubMed ID: 15613622
[TBL] [Abstract][Full Text] [Related]
10. Pregnant rats are refractory to the natriuretic actions of atrial natriuretic peptide.
Masilamani S; Castro L; Baylis C
Am J Physiol; 1994 Dec; 267(6 Pt 2):R1611-6. PubMed ID: 7810772
[TBL] [Abstract][Full Text] [Related]
11. The natriuretic and diuretic response to dopamine is maintained during rat pregnancy.
Sasser JM; Baylis C
Am J Physiol Renal Physiol; 2008 Jun; 294(6):F1342-4. PubMed ID: 18400873
[TBL] [Abstract][Full Text] [Related]
12. Early treatment with cGMP phosphodiesterase inhibitor ameliorates progression of renal damage.
Rodríguez-Iturbe B; Ferrebuz A; Vanegas V; Quiroz Y; Espinoza F; Pons H; Vaziri ND
Kidney Int; 2005 Nov; 68(5):2131-42. PubMed ID: 16221212
[TBL] [Abstract][Full Text] [Related]
13. Acute phosphodiesterase 5 inhibition mimics hemodynamic effects of B-type natriuretic peptide and potentiates B-type natriuretic peptide effects in failing but not normal canine heart.
Forfia PR; Lee M; Tunin RS; Mahmud M; Champion HC; Kass DA
J Am Coll Cardiol; 2007 Mar; 49(10):1079-88. PubMed ID: 17349888
[TBL] [Abstract][Full Text] [Related]
14. Mechanisms contributing to renal resistance to atrial natriuretic peptide in rats with common bile-duct ligation.
Ni X; Cheng Y; Cao L; Gardner DG; Humphreys MH
J Am Soc Nephrol; 1996 Oct; 7(10):2110-8. PubMed ID: 8915970
[TBL] [Abstract][Full Text] [Related]
15. Modulation of ANP-dependent effects of endothelin by inhibitors of neutral endopeptidase and cGMP phosphodiesterase.
Valentin JP; Qiu C; Wiedemann E; Gardner DG; Humphreys MH
J Pharmacol Exp Ther; 1995 May; 273(2):744-52. PubMed ID: 7752077
[TBL] [Abstract][Full Text] [Related]
16. Angiotensin-converting enzyme inhibition prevents myocardial infarction-induced increase in renal cortical cGMP and cAMP phosphodiesterase activities.
Clauss F; Charloux A; Piquard F; Doutreleau S; Talha S; Zoll J; Lugnier C; Geny B
Fundam Clin Pharmacol; 2015 Aug; 29(4):352-61. PubMed ID: 25939307
[TBL] [Abstract][Full Text] [Related]
17. Sildenafil citrate (Viagra) enhances vasodilatation by atrial natriuretic peptide in normal dogs.
Ishikura F; Beppu S; Asanuma T; Seward JB; Khandheria BK
Circ J; 2007 Dec; 71(12):1965-9. PubMed ID: 18037755
[TBL] [Abstract][Full Text] [Related]
18. Atrial natriuretic peptide attenuates pressor but enhances natriuretic responses to angiotensin II in pregnant conscious goats.
Olsson K; Hossaini-Hilali J; Eriksson L
Acta Physiol Scand; 1992 Aug; 145(4):385-94. PubMed ID: 1388314
[TBL] [Abstract][Full Text] [Related]
19. Response to atrial natriuretic peptide, endopeptidase 24.11 inhibitor and C-ANP receptor ligand in the rat.
Wilkins MR; Settle SL; Kirk JE; Taylor SA; Moore KP; Unwin RJ
Br J Pharmacol; 1992 Sep; 107(1):50-7. PubMed ID: 1330165
[TBL] [Abstract][Full Text] [Related]
20. Renal effects of prolonged intrarenal infusions of angiotensin II and atrial natriuretic peptide in sheep.
Fan L; Mukaddam-Daher S; Javeshghani D; Quillen E; Gutkowska J
J Cardiovasc Pharmacol; 1999 Sep; 34(3):427-33. PubMed ID: 10471003
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
